Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

100 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Therapeutic approach in glioblastoma multiforme with primitive neuroectodermal tumor components: Case report and review of the literature.
Prelaj A, Rebuzzi SE, Caffarena G, Giròn Berrìos JR, Pecorari S, Fusto C, Caporlingua A, Caporlingua F, Di Palma A, Magliocca FM, Salvati M, Tomao S, Bianco V. Prelaj A, et al. Among authors: rebuzzi se. Oncol Lett. 2018 May;15(5):6641-6647. doi: 10.3892/ol.2018.8102. Epub 2018 Feb 21. Oncol Lett. 2018. PMID: 29616127 Free PMC article.
Neoadjuvant Chemotherapy in Neuroendocrine Bladder Cancer: A Case Report.
Prelaj A, Rebuzzi SE, Magliocca FM, Speranza I, Corongiu E, Borgoni G, Perugia G, Liberti M, Bianco V. Prelaj A, et al. Among authors: rebuzzi se. Am J Case Rep. 2016 Apr 13;17:248-53. doi: 10.12659/ajcr.896989. Am J Case Rep. 2016. PMID: 27072610 Free PMC article.
Evaluation of the efficacy of cisplatin-etoposide and the role of thoracic radiotherapy and prophylactic cranial irradiation in LCNEC.
Prelaj A, Rebuzzi SE, Del Bene G, Giròn Berrìos JR, Emiliani A, De Filippis L, Prete AA, Pecorari S, Manna G, Ferrara C, Rossini D, Longo F. Prelaj A, et al. Among authors: rebuzzi se. ERJ Open Res. 2017 Mar 29;3(1):00128-2016. doi: 10.1183/23120541.00128-2016. eCollection 2017 Jan. ERJ Open Res. 2017. PMID: 28382303 Free PMC article.
Non-conventional fotemustine schedule as second-line treatment in recurrent malignant gliomas: Survival across disease and treatment subgroup analysis and review of the literature.
Prelaj A, Rebuzzi SE, Grassi M, Salvati M, D'Elia A, Buttarelli F, Ferrara C, Tomao S, Bianco V. Prelaj A, et al. Among authors: rebuzzi se. Mol Clin Oncol. 2019 Jan;10(1):58-66. doi: 10.3892/mco.2018.1746. Epub 2018 Oct 16. Mol Clin Oncol. 2019. PMID: 30655978 Free PMC article.
Beyond First-Line Immunotherapy: Potential Therapeutic Strategies Based on Different Pattern Progressions: Oligo and Systemic Progression.
Prelaj A, Pircher CC, Massa G, Martelli V, Corrao G, Lo Russo G, Proto C, Ferrara R, Galli G, De Toma A, Genova C, Jereczek-Fossa BA, Braud F, Garassino MC, Rebuzzi SE. Prelaj A, et al. Among authors: rebuzzi se. Cancers (Basel). 2021 Mar 15;13(6):1300. doi: 10.3390/cancers13061300. Cancers (Basel). 2021. PMID: 33803958 Free PMC article. Review.
Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer.
Rebuzzi SE, Zullo L, Rossi G, Grassi M, Murianni V, Tagliamento M, Prelaj A, Coco S, Longo L, Dal Bello MG, Alama A, Dellepiane C, Bennicelli E, Malapelle U, Genova C. Rebuzzi SE, et al. Int J Mol Sci. 2021 Mar 5;22(5):2625. doi: 10.3390/ijms22052625. Int J Mol Sci. 2021. PMID: 33807876 Free PMC article. Review.
Prognostic scores including peripheral blood-derived inflammatory indices in patients with advanced non-small-cell lung cancer treated with immune checkpoint inhibitors.
Rebuzzi SE, Prelaj A, Friedlaender A, Cortellini A, Addeo A, Genova C, Naqash AR, Auclin E, Mezquita L, Banna GL. Rebuzzi SE, et al. Crit Rev Oncol Hematol. 2022 Nov;179:103806. doi: 10.1016/j.critrevonc.2022.103806. Epub 2022 Sep 8. Crit Rev Oncol Hematol. 2022. PMID: 36087850 Review.
100 results